5UKE

NMR structure of monomeric human IRAK-M Death Domain R56D, Y61E mutant


Experimental Data Snapshot

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

The IL-33-PIN1-IRAK-M axis is critical for type 2 immunity in IL-33-induced allergic airway inflammation.

Nechama, M.Kwon, J.Wei, S.Kyi, A.T.Welner, R.S.Ben-Dov, I.Z.Arredouani, M.S.Asara, J.M.Chen, C.H.Tsai, C.Y.Nelson, K.F.Kobayashi, K.S.Israel, E.Zhou, X.Z.Nicholson, L.K.Lu, K.P.

(2018) Nat Commun 9: 1603-1603

  • DOI: 10.1038/s41467-018-03886-6

  • PubMed Abstract: 
  • Interleukin 33 (IL-33) is among the earliest-released cytokines in response to allergens that orchestrate type 2 immunity. The prolyl cis-trans isomerase PIN1 is known to induce cytokines for eosinophil survival and activation by stabilizing cytokine ...

    Interleukin 33 (IL-33) is among the earliest-released cytokines in response to allergens that orchestrate type 2 immunity. The prolyl cis-trans isomerase PIN1 is known to induce cytokines for eosinophil survival and activation by stabilizing cytokines mRNAs, but the function of PIN1 in upstream signaling pathways in asthma is unknown. Here we show that interleukin receptor associated kinase M (IRAK-M) is a PIN1 target critical for IL-33 signaling in allergic asthma. NMR analysis and docking simulations suggest that PIN1 might regulate IRAK-M conformation and function in IL-33 signaling. Upon IL-33-induced airway inflammation, PIN1 is activated for binding with and isomerization of IRAK-M, resulting in IRAK-M nuclear translocation and induction of selected proinflammatory genes in dendritic cells. Thus, the IL-33-PIN1-IRAK-M is an axis critical for dendritic cell activation, type 2 immunity and IL-33 induced airway inflammation.


    Organizational Affiliation

    Department of Molecular Biology & Genetics, Cornell University, Ithaca, NY, 14853, USA.,Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. klu@bidmc.harvard.edu.,Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA.,Institute for Translational Medicine, Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Fujian Medical University, Fuzhou, 350108, Fujian, China. klu@bidmc.harvard.edu.,Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. klu@bidmc.harvard.edu.,Department of Nephrology and Hypertension, Hadassah-Hebrew Medical Center, 91120, Jerusalem, Israel.,Department of Microbial Pathogenesis & Immunology, Texas A&M Health Science Center, College Station, TX, 77843, USA.,Department of Molecular Biology & Genetics, Cornell University, Ithaca, NY, 14853, USA. lkn2@cornell.edu.,Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Interleukin-1 receptor-associated kinase 3
A
124Homo sapiensMutation(s): 2 
Gene Names: IRAK3
EC: 2.7.11.1
Find proteins for Q9Y616 (Homo sapiens)
Go to Gene View: IRAK3
Go to UniProtKB:  Q9Y616
Experimental Data & Validation

Experimental Data

  • Method: SOLUTION NMR
  • Conformers Calculated: 100 
  • Conformers Submitted: 20 
  • Selection Criteria: structures with the lowest energy 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Heart, Lung, and Blood InstituteUnited StatesR01-HL111430

Revision History 

  • Version 1.0: 2018-01-24
    Type: Initial release
  • Version 1.1: 2019-02-06
    Type: Data collection, Database references